Bristol-Myers Squibb has signed another deal to build its capabilities in antibody-drug conjugates for cancer, paying $100 million upfront to take control of an Orum Therapeutics candidate with a different take on the class.
The deal – with a potential value of $180 million – is focusing on ORM-6151, which combines the properties of ADCs and protein degraders, another emerging therapeutic category in oncology.
